BioCentury
ARTICLE | Clinical News

Amonafide: Phase III amend

October 19, 2009 7:00 AM UTC

Antisoma will amend the ongoing, open-label Phase III ACCEDE trial evaluating AS1413 to change the primary endpoint to initial remission rate from confirmed remission (CR) rate in order to remove the ...